About us
SVac is poised to accelerate the biologics revolution given that it is non-immunogenic and has broad utility."


Amarna, with its SVac viral vector platform, is the only company to have developed a reliable production system for SV40-based viral vectors. As a result, Amarna is uniquely placed to produce SVac in the large quantities required for clinical trials and commercialization across a wide range of chronic or life-threatening conditions.

Amarna has state-of-the-art R&D facilities in the Leiden BioScience Park, Leiden the Netherlands and in El Parque Tecnológico de Ciencias de la Salud in Granada, Spain.

Amarna can manufacture SVac vector particles at its Leiden facility and is in the process of setting up a GMP manufacturing facility in Granada.

Amarna has dedicated R&D capabilities with specific expertise in RNA interference, infectious and neurodegenerative diseases, with a qualified and experienced team to support the development of a pipeline of innovative proprietary SVac-based drug candidates.